Clinical Trial Detail

NCT ID NCT04140487
Title Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Azacitidine + Gilteritinib + Venetoclax

Age Groups: senior adult

Additional content available in CKB BOOST